Patients with AAV and kidney involvement who take SGLT-2 inhibitors may have a reduced risk for ESRD and kidney transplant ...

MADRID — Nearly half of people with type 2 diabetes (T2D) currently recommended to receive sodium-glucose cotransporter 2 (SGLT2) inhibitors for kidney protection would not actually benefit from them, ...

Thailand: Use of sodium-glucose co-transporter-2 inhibitors (SGLT2is) may help reduce the risk of kidney stone formation in ...

Learn about the current medication options for managing type 2 diabetes and chronic kidney disease, including SGLT2 ...

Jennifer Green, MD, provides considerations for the use of SGLT2 inhibitors in treatment of CKD. Ryan Haumschild, PharmD, MS, MBA: As we talk about SGLT2s [sodium-glucose cotransporter-2 inhibitors] ...

Hydration is key for people with diabetic kidney disease. Learn how much water to drink, why it matters for blood sugar and ...

Please provide your email address to receive an email when new articles are posted on . The chart review shows strong growth in the use of SGLT2 inhibitors. Management of patients with CKD is crucial ...

SGLT2 inhibitors reduce the risk for adverse kidney outcomes across most high-risk populations with CKD, heart failure, and/or type 2 diabetes. Sodium glucose cotransporter 2 inhibitors (SGLT2i) ...

SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from ...

Observational study data suggest that SGLT2 inhibitor use reduces risks for kidney and cardiovascular events even in patients with an eGFR less than 15 mL/min/1.73 m2 who have type 2 diabetes.

Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibition may confer similar kidney and CV outcomes vs. GLP-1 receptor agonists for diabetes. Results ...

Use vs non-use of sodium-glucose cotransporter 2 inhibitors by older patients with CKD stages 4-5D is significantly associated with reductions in all-cause mortality risk at 6, 12, and 60 months.